Skip to main content
Register for full year results conference call. March 27th. Register Today

H1 2019 Interim Results

investor

Interim Results Presentation:

Download Presentation

Interim Results 30 June 2019:

Interim Results

H1 2019 Key Stats

€21.9m
EBITDA, up 119%
7%
Organic GP Growth YoY
14.3%
ROCE H1 2019
9.3c
Adjusted EPS, up 157%

Group Highlights

€159.6m

2018 GP(Pro forma)

Employees
Partnering with 7 of the top 10 pharma companies
and 6 of the top 10 medical device companies